Fundraising Fox
iSpecimen
NASDAQ: ISPCWoburn, US · Founded 2009 · Delaware corporation · 17 employees on LinkedIn
Find your way into iSpecimen
310 people in our graph can introduce you to the iSpecimen team.
Sign up to see every warm intro you have to iSpecimen
- Paths you didn't know you had: your email and LinkedIn already hold routes to the iSpecimen team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
iSpecimen operates an online marketplace that connects medical researchers to a global network of biospecimen providers, offering access to human biospecimens such as diagnostic remnant, banked, and prospective collections. The platform serves the biospecimen procurement needs of researchers in the life sciences and healthcare research industry.
Founders & leadership
iSpecimen was founded in 2009 by Jill Mullan and Christopher Ianelli.
JM
Jill MullanCo-founder, Chief Operating Officer, Chief Compliance Officer, Chief Marketing Officer, Treasurer2010–2022Jill Mullan is co-founder and co-CEO of Joined Bio, an AI-enabled platform for patient recruitment in life science research. She previously co-founded iSpecimen, which she grew to a public company (NASDAQ: ISPC) while holding multiple executive roles, and earlier managed a major product line at Avid Technology and served as a founding member at Storigen Systems.
CI
Christopher IanelliFounder, CEO, & Board Director2009–2022Before founding his current company, Christopher Ianelli spent seven years working in digital agencies as a consultant and software developer. He is the CEO of Storyblok, a headless content management system that lets developers build flexible components which marketers manage through a visual editor, with published content delivered via API across websites, mobile, and other digital platforms.
KF
Katharyn FieldPresident
Board
GS
George SchollBoard director
AR
Andrew RossBoard director
SY
Siyun YangBoard director
AD
Avtar DhaliwalBoard director
AL
Anthony LauBoard director
Reported raises · per SEC filings
Form D private placements$40.6M disclosed across 7 rounds · 2014–2026
▶$2.5MraisedMay 2026 · 2 investors · OtherRule 506(b)
▶$2.5MraisedMay 2026 · 2 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Anthony LauDirector
- Arphing (Tommy) LeeDirector
- Avtar DhaliwalDirector
- Katharyn FieldExecutive Officer
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- Sales commissions
- $100K
- Placement agents
- E.F. Hutton & Co.
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedJan 2026 · 3 investors · OtherRule 506(b)
▶$5.5MraisedJan 2026 · 3 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Siyun YangDirector
- Arphing (Tommy) LeeDirector
- Anthony LauDirector
- Katharyn FieldExecutive Officer
- Avtar DhaliwalDirector
- Offering amount
- $5.5M
- Amount sold
- $5.5M
- Sales commissions
- $220K
- Placement agents
- E.F. Hutton & Co.
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.8MraisedAug 2025 · 4 investors · OtherRule 506(b)
▶$1.8MraisedAug 2025 · 4 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Siyun YangDirector
- Avtar DhaliwalDirector
- Katharyn FieldExecutive Officer
- Anthony LauDirector
- Robert Bradley LimExecutive Officer
- Offering amount
- $1.8M
- Amount sold
- $1.8M
- Sales commissions
- $70K
- Placement agents
- Westpark Capital, Inc
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$21MraisedDec 2021 · 4 investors · Other Health CareRule 506(b)
▶$21MraisedDec 2021 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Benjamin BielakExecutive Officer
- Steven GullansDirector
- John L. Brooks IIIDirector
- Margaret H. LawrenceDirector
- Tracy CurleyExecutive Officer
- Andrew RossDirector
- George SchollDirector
- Jill MullanExecutive Officer, Director
- Christopher J. IanelliExecutive Officer, Director
- Offering amount
- $21M
- Amount sold
- $21M
- Sales commissions
- $1.3M
- Placement agents
- ThinkEquity LLC
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$800KraisedAug 2018 · 3 investors · Other Health CareRule 506(b)
▶$800KraisedAug 2018 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Christopher J. IanelliExecutive Officer, Director
- Jill MullanDirector
- Andrew RossDirector
- George SchollDirector
- Offering amount
- $4M
- Amount sold
- $800K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedMar 2017 · 1 investors · Other Health CareRule 506(b)
▶$500KraisedMar 2017 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- George SchollDirector
- Andrew RossDirector
- Jill MullanExecutive Officer, Director
- Christopher IanelliExecutive Officer, Director
- Offering amount
- $5.5M
- Amount sold
- $500K
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.6MraisedSep 2014 · 13 investors · Other Health CareRule 506(b)
▶$8.6MraisedSep 2014 · 13 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jill MullanExecutive Officer, Director
- Christopher IanelliExecutive Officer, Director
- Andrew RossDirector
- George SchollDirector
- Bruce CrannaExecutive Officer
- Offering amount
- $8.6M
- Amount sold
- $8.6M
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Precision For MedicinePrecision for Medicine is a contract research organization that provides clinical trial management and regulatory support for drug development programs, including oncology, hematology, cell and gene therapy, CAR-T, and radiopharmaceutical trials. It serves pharmaceutical and biotech sponsors running multinational Phase I–IV studies.
LabcorpLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.
Companies working in the same space as iSpecimen.
Frequently asked questions
- What does iSpecimen do?
- iSpecimen operates an online marketplace that connects medical researchers to a global network of biospecimen providers, offering access to human biospecimens such as diagnostic remnant, banked, and prospective collections. The platform serves the biospecimen procurement needs of researchers in the life sciences and healthcare research industry.
- Who founded iSpecimen?
- iSpecimen was founded by Jill Mullan, Christopher Ianelli in 2009.
- How much funding has iSpecimen raised?
- iSpecimen has disclosed $40.6M raised across 7 rounds.
- Where is iSpecimen headquartered?
- iSpecimen is headquartered in Woburn, US.